A Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer-Reference-Cited by-同舟云学术

A Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer

Published:2011-09 Issue:3 Volume:186 Page:889-897
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Crawford E. David¹,Tombal Bertrand²,Miller Kurt³,Boccon-Gibod Laurent⁴,Schröder Fritz⁵,Shore Neal⁶,Moul Judd W.⁷,Jensen Jens-Kristian⁸,Olesen Tine Kold⁸,Persson Bo-Eric⁹

Affiliation:

1. University of Colorado Denver, Aurora, Colorado

2. Cliniques Universitaires Saint Luc/Université Catholique de Louvain, Brussels, Belgium

3. Charité Universitätsmedizin Berlin, Berlin, Germany

4. Centre Hospitalier Universitaire Hôpital Bichat-Claude Bernard, Paris, France

5. Erasmus Medical Center, Rotterdam, The Netherlands

6. Carolina Urologic Research Center, Myrtle Beach, South Carolina

7. Duke University Medical Center, Durham, North Carolina

8. Ferring Pharmaceuticals, Copenhagen, Denmark

9. Saint-Prex, Switzerland

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference24 articles.

1. Testosterone surge: rationale for gonadotropin-releasing hormone blockers?;Van Poppel;Urology,2008

3. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in prostate cancer patients;Klotz;BJU Int,2008

4. Will GnRH antagonists improve prostate cancer treatment?;Huhtaniemi;Trends Endocrinol Metab,2009

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The disordering effect of SARMs on a biomembrane model;Physical Chemistry Chemical Physics;2024

2. Testosterone suppression combined with high dose estrogen as potential treatment of SARS-CoV-2. A mini review;Heliyon;2022-12

3. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021;Journal of Hematology & Oncology;2022-10-08

4. Relugolix in the management of prostate cancer;Expert Review of Anticancer Therapy;2022-07-27

5. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials;Signal Transduction and Targeted Therapy;2022-06-24